If you have been diagnosed with a high-risk basal cell carcinoma, you may hear about several ways of assessing and treating your tumour. Mohs micrographic surgery and standard surgical excision are two established surgical approaches, while newer imaging research is examining whether your skin cancer can be assessed more accurately without relying on biopsy alone.
It is important to separate these areas of research. The OCTOPUS study investigates optical coherence tomography and line-field confocal OCT for diagnosing keratinocyte cancers and precancers; it is not the randomised trial that compared Mohs surgery with standard excision. Separate clinical trials provide the evidence that can help your specialist compare these surgical treatments.
What Is the OCTOPUS Study Actually Investigating?
OCTOPUS stands for Optical Coherence Tomography in OutPatient dermatology UnitS. If you take part in this type of assessment, non-invasive imaging is used to examine your skin lesion before the usual histological diagnosis is established.
Researchers are studying whether OCT and LC-OCT can help clinicians identify keratinocyte cancers, including basal cell carcinoma, and assess characteristics such as subtype. For you, the potential benefit is a faster and less invasive diagnostic pathway if future evidence shows that these technologies are sufficiently accurate.
Does the OCTOPUS Study Compare Mohs Surgery With Standard Excision?
No. You should not interpret OCTOPUS as the name of the randomised surgical trial comparing Mohs micrographic surgery with standard excision. The current OCTOPUS research focuses primarily on diagnostic imaging rather than deciding which surgical procedure gives you the lowest recurrence risk.
The comparison between Mohs surgery and standard excision comes from separate Dutch randomised research involving primary and recurrent facial basal cell carcinomas. Understanding this distinction helps you interpret the evidence correctly and avoids attributing surgical findings to the wrong study.
What Is Basal Cell Carcinoma?
Basal cell carcinoma, or BCC, is a common form of skin cancer that usually develops in areas of your skin that have received substantial ultraviolet exposure. You may notice a persistent lesion, a pearly or shiny bump, an ulcer that does not heal or an area that repeatedly crusts or bleeds.
Most BCCs grow relatively slowly and rarely spread to distant organs, but you should not assume that this makes them harmless. If your tumour continues to grow, it can damage nearby skin and important structures, particularly when it develops around your eyes, nose, ears or lips.
What Makes Your Basal Cell Carcinoma High Risk?
Your BCC may be considered higher risk when certain features increase the likelihood of incomplete removal, recurrence or difficult reconstruction. These factors can include your tumour’s location, size, borders, microscopic subtype and whether it has previously been treated.
Your overall circumstances also matter. If your immune system is suppressed, your tumour has grown around a nerve or your previous surgery left involved margins, your specialist may need to consider a more specialised surgical or multidisciplinary approach.
Which Factors Can Influence Your Surgical Treatment?
Your specialist does not choose between Mohs surgery and standard excision from the tumour name alone. Your treatment should reflect the behaviour of your particular BCC, its anatomical location and how much surrounding tissue can safely be removed.
The table below can help you understand some of the factors your dermatologist or surgeon may consider when discussing your treatment.
| Factor | Why It Matters for You | When Mohs May Be Considered | When Standard Excision May Be Appropriate |
| Location | Your eyes, nose, lips and ears have important functional and cosmetic structures | When detailed margin control and tissue preservation are priorities | When a suitable margin can be removed safely |
| Recurrent tumour | Your recurrent BCC may extend beyond the visible edge | Often considered for selected recurrent facial BCCs | Selected cases may still be suitable after specialist review |
| Poorly defined borders | Your tumour may be harder to map clinically | Staged margin assessment can identify hidden extension | More suitable when your tumour is clearly defined |
| Aggressive histology | Some subtypes can grow irregularly through surrounding skin | May provide useful margin control | May remain suitable in selected circumstances |
| Large tumour | Your surgery may require more extensive reconstruction | Can help avoid unnecessary removal in constrained sites | Appropriate where adequate margins can be achieved |
| Previous incomplete excision | Your residual tumour may remain beyond the previous scar | Can map remaining tumour during staged surgery | Re-excision may be suitable in selected cases |
| Perineural involvement | Your tumour may be growing around a nerve | Specialist margin-controlled surgery may form part of treatment | Standard excision alone may not always be sufficient |
| Immunosuppression | Your tumour behaviour and future skin-cancer risk may differ | May be considered alongside other high-risk features | Depends on your tumour and general health |
| Procedure tolerance | Mohs can require several stages during your visit | Suitable if you can tolerate staged local-anaesthetic surgery | May be more practical when a shorter procedure is appropriate |
What Is Standard Surgical Excision?
If you have standard surgical excision, your surgeon removes the visible BCC together with a predetermined margin of surrounding skin. The wound is then repaired according to its size, location and the amount of tissue that has been removed.
Your specimen is subsequently examined under a microscope to assess the margins. If cancer cells are present at or close to an important margin, you may need further treatment depending on your tumour characteristics and pathology results.
What Is Mohs Micrographic Surgery?
If you undergo Mohs micrographic surgery, your tumour is removed in stages and the margins are examined while you remain at the treatment centre. Your surgeon can then remove additional tissue specifically from areas where microscopic tumour remains.
This mapped approach can be particularly useful when preserving healthy tissue is important for you. However, you should not assume that Mohs removes no normal skin or guarantees a tiny scar, because the final defect depends on how far your tumour actually extends.
How Is Mohs Surgery Different From Standard Excision?
The major difference for you is how and when the surgical margins are assessed. With standard excision, your specimen is normally processed by a pathology laboratory after your procedure, whereas Mohs allows mapped microscopic margin assessment during the operation.
This can help your surgeon target further removal only where tumour remains. Standard excision nevertheless remains an effective treatment for many BCCs, so you should not interpret the availability of Mohs as meaning standard surgery is inferior for every tumour.
Why Can Tissue Preservation Matter to You?
If your BCC is located near your eyelid, nose, ear or lip, every millimetre of tissue can influence how the area is reconstructed. Preserving unaffected skin may give your surgeon more options for maintaining your appearance and normal function.
You should still expect a surgical wound and scar after either procedure. Mohs is designed to combine margin assessment with tissue conservation, but your final defect can become larger than the visible tumour if microscopic cancer extends further than expected.
Does Mohs Surgery Always Create a Smaller Scar?
No. You may initially expect Mohs to produce the smallest possible scar because it is described as tissue-sparing, but your visible tumour does not always show its complete microscopic extent.
If additional Mohs stages are needed, your final surgical defect may be larger than you expected. Your scar will also depend on the location of your cancer, reconstruction technique, wound tension, individual healing and how your scar changes over time.
What Did the Randomised Mohs vs Excision Research Study?
Separate Dutch randomised research compared Mohs surgery with standard excision for selected primary and recurrent facial BCCs. If you are reviewing this evidence, you should know that the primary tumours included high-risk features such as facial H-zone location, a diameter of at least 1 cm or aggressive histology.
The investigators followed participants to compare recurrence after the two procedures. This gives your specialist stronger comparative evidence than relying only on separate case series, although the findings should still be applied to the type of BCC you actually have.
Research Insight:
At ten years, the cumulative recurrence probability for primary facial BCC was reported as 4.4% after Mohs surgery and 12.2% after standard excision. Although this numerically favoured Mohs, you should know that the difference for primary BCC did not reach statistical significance in that analysis.
For recurrent facial BCC, recurrence was reported as 3.9% after Mohs and 13.5% after standard excision, with a statistically significant difference. For you, these results support the particular importance of Mohs in selected recurrent facial tumours rather than proving that every primary BCC needs Mohs surgery.
Does Mohs Surgery Reduce Your Risk of Recurrence?
Mohs can provide excellent disease control for appropriately selected high-risk and recurrent BCCs. If your tumour has irregular microscopic extensions, real-time mapped margin assessment may help your surgeon identify areas that might otherwise be difficult to predict clinically.
You should not understand this as a guarantee that your cancer can never return. Even after apparently complete treatment, your recurrence risk is not zero, and having one BCC can also mean you have an increased risk of developing another skin cancer elsewhere.
What Did the Research Show About Cosmetic Results?
You may assume that better tissue preservation automatically means that patients always rate their cosmetic outcome as better after Mohs. However, the randomised evidence cited in the source material did not demonstrate a statistically significant difference in patient-reported facial aesthetic outcomes between the two surgical approaches.
Your personal cosmetic result depends on much more than the name of your operation. Your tumour size, location, hidden spread, repair method, scar formation and individual healing can all influence how your skin looks after recovery.
Why Does Functional Preservation Matter?
If your tumour is close to your eyelid, nose, ear or lip, your treatment must consider more than removing cancer. Your surgeon may also need to protect structures involved in vision, breathing, hearing, facial movement or the normal shape of your face.
A tissue-preserving approach may be especially valuable when your anatomy leaves little room for unnecessary removal. Your treatment plan should therefore balance cancer clearance with the functional consequences of your surgery.
What Happens If Your Surgical Margins Are Not Clear?
If standard pathology shows cancer cells at an excision margin, you may need another procedure or another form of treatment. Your next step will depend on your tumour subtype, anatomical location, which margin is involved and your previous treatment history.
With Mohs, your surgeon continues staged removal while microscopic tumour is identified in the mapped margin. This is one reason Mohs can be useful when your BCC has poorly defined borders or has returned after previous treatment.
How Important Is Histological Assessment?
Histology helps your clinical team confirm the type of BCC you have and assess whether your tumour has features associated with higher risk. Your pathology can therefore influence both your initial treatment plan and what happens after your surgery.
You should remember that margin assessment is performed differently in Mohs and conventional excision. Both approaches use microscopic examination, but Mohs is specifically designed to map the peripheral and deep margins during your procedure.
What Can You Expect During Recovery?
Your recovery after either operation depends on the size and location of your surgical defect, the type of repair and your general health. You may need stitches, a local skin flap, a graft or another reconstruction depending on the area being treated.
Your clinical team will explain wound care and any activities you need to avoid during healing. Following your instructions, attending follow-up when advised and reporting unexpected bleeding, infection, wound breakdown or worsening pain can help your recovery stay on track.
What Risks Should You Understand Before Surgery?
Both procedures can cause bleeding, infection, bruising, discomfort, wound problems, scarring and changes in sensation. Depending on where your tumour is located, you may also face more specific risks involving nearby nerves or important anatomical structures.
Your surgeon should explain the risks that apply to you before your operation. You should also have an opportunity to discuss your likely reconstruction, expected scar and what may happen if your tumour extends further than predicted.
UK Guidance Note
UK basal cell carcinoma guidance recognises that treatment should be selected according to tumour risk and individual clinical circumstances. If your BCC is suitable for standard surgical excision, this remains an established treatment rather than an inferior alternative simply because Mohs surgery exists.
Mohs may be particularly relevant when your tumour has features that make detailed margin control or tissue conservation especially important. Your specialist should therefore base the recommendation on your tumour rather than automatically choosing the same procedure for every facial BCC.
Clinical Tip
If you are told that you need Mohs surgery, ask which feature of your tumour makes the technique useful for you. Understanding whether the reason is your tumour location, recurrence, aggressive histology, poorly defined borders or another factor can make your treatment decision easier to understand.
If standard excision is recommended instead, you can also ask why it is appropriate for your case and how your margins will be assessed. You should feel able to understand the benefits, limitations and alternatives before agreeing to your surgery.
Why Is Long-Term Follow-Up Important?
Some BCC recurrences can develop several years after treatment, so a short period without recurrence does not always tell you the complete story. In the ten-year randomised follow-up, a meaningful proportion of recurrences occurred after the first five years.
Your follow-up requirements will depend on your tumour risk and your wider history of skin cancer. You should also continue checking your own skin and report new, changing, bleeding or non-healing lesions rather than waiting for a routine appointment.
What Does the OCTOPUS Research Mean for You?
The OCTOPUS study addresses a different part of your skin-cancer journey from Mohs or excision. Instead of comparing surgery, it investigates whether OCT and LC-OCT imaging can help clinicians diagnose and subtype keratinocyte cancers without relying entirely on conventional biopsy pathways.
If future trials confirm sufficient diagnostic accuracy and cost-effectiveness, you could potentially benefit from faster assessment and fewer invasive diagnostic procedures in selected situations. However, these imaging technologies do not currently mean that histology or appropriate treatment can simply be abandoned.
Could OCT Imaging Change BCC Treatment Planning?
Better non-invasive imaging could eventually give your dermatologist more information about a suspicious lesion before treatment. If the technology can reliably identify tumour characteristics, it may help your clinical team plan your next step more efficiently.
You should regard this as developing research rather than a replacement for current diagnostic standards. Your dermatologist still needs to interpret the lesion in the context of your examination, medical history and any histological information required for safe management.
Why Should Your Treatment Be Individualised?
Two people can both have basal cell carcinoma but need different treatment because their tumours behave differently. Your BCC location, size, histological subtype, borders, previous treatment and general health can all change the balance between Mohs and standard excision.
Your preferences also matter, particularly when you are discussing scars, procedure length, reconstruction and follow-up. Individualised planning helps your specialist choose a treatment that aims to provide reliable cancer control while respecting your functional and cosmetic priorities.
Evidence Note
The strongest surgical comparison discussed here comes from a separate randomised Dutch trial rather than the OCTOPUS study. At ten years, recurrence numerically favoured Mohs for both primary and recurrent facial BCC, but statistical significance was demonstrated for recurrent BCC and not for the primary-BCC comparison.
For you, this means the evidence supports selective use rather than a simple rule that Mohs is always better. Your treatment should be based on your actual tumour risk, anatomical site and clinical circumstances rather than on one recurrence statistic alone.
Myth vs Fact
| Myth | Fact |
| OCTOPUS is the randomised Mohs-versus-excision trial | OCTOPUS investigates OCT and LC-OCT diagnostic imaging |
| Every facial BCC needs Mohs | Your risk depends on location, size, borders, histology and previous treatment |
| Standard excision does not examine margins | Your excised specimen is examined histologically |
| Mohs removes no healthy skin | Your visible tumour and mapped margin tissue still have to be removed |
| Mohs guarantees no recurrence | Your recurrence risk is low in selected cases but never zero |
| Mohs always creates the smallest scar | Your final defect depends on microscopic tumour spread |
| Mohs always looks better cosmetically | Randomised research did not establish a significant patient-reported aesthetic advantage |
| Standard excision cannot treat high-risk BCC | It remains suitable for selected higher-risk tumours |
| Mohs is always a quick appointment | You may require several stages over several hours |
| Clear margins mean you never need follow-up | Your future surveillance depends on your overall skin-cancer risk |
Key Takeaways
- You should know that OCTOPUS studies diagnostic OCT and LC-OCT imaging rather than Mohs versus standard excision.
- Your Mohs-versus-excision evidence comes from separate randomised clinical research.
- Your BCC treatment depends on tumour location, size, borders, histological subtype and previous treatment.
- You may benefit from Mohs when detailed margin control and preservation of healthy tissue are especially important.
- Your standard excision specimen is still examined histologically for margin clearance.
- You should not assume that Mohs removes no healthy tissue or guarantees the smallest scar.
- Your ten-year recurrence risk in the randomised study numerically favoured Mohs for both primary and recurrent facial BCC.
- You should note that the significant recurrence advantage at ten years was demonstrated for recurrent facial BCC, not the primary-BCC comparison.
- Your cosmetic result depends on your tumour, final defect, reconstruction and healing rather than procedure name alone.
- You may need long-term follow-up because some recurrences can develop years after treatment.
- Your surgeon should explain why the recommended operation is suitable for your individual tumour.
- You should seek assessment for any persistent, bleeding, changing or non-healing skin lesion.
Frequently Asked Questions
1. What is the OCTOPUS study?
The OCTOPUS study investigates whether optical coherence tomography and line-field confocal OCT can help diagnose keratinocyte cancers and precancers. You should not confuse it with the separate randomised clinical research comparing Mohs surgery with standard excision.
2. What makes your basal cell carcinoma high risk?
Your BCC may be considered high risk because of factors such as its location, size, poorly defined borders, aggressive histological subtype, previous recurrence or other clinical features. Your specialist will assess these factors together rather than using location alone.
3. What is the main difference between Mohs and standard excision?
With Mohs, your margins are mapped and examined during staged surgery, while standard excision removes your tumour with a planned margin and sends the specimen for subsequent histological assessment. Both techniques can be appropriate depending on your BCC.
4. Does Mohs surgery lower your recurrence risk?
For selected recurrent facial BCCs, long-term randomised evidence showed a lower recurrence probability after Mohs than after standard excision. You should not apply that result automatically to every primary or low-risk BCC.
5. Does Mohs surgery always preserve more healthy skin?
Mohs is designed to target additional removal to areas where microscopic tumour remains, which can help preserve tissue in anatomically sensitive areas. However, your final defect still depends on the true hidden extent of your cancer.
6. Will Mohs give you a better-looking scar?
Not necessarily. Your cosmetic result depends on tumour size, location, reconstruction and healing, and the randomised research discussed here did not demonstrate a statistically significant difference in patient-reported facial aesthetics.
7. Can standard excision still be suitable for a high-risk BCC?
Yes. Your specialist may still recommend standard excision for selected higher-risk tumours when appropriate margins can be achieved safely. You should discuss why the chosen approach is suitable for your specific BCC.
8. Can your BCC return after surgery?
Yes. Your recurrence risk is usually low after appropriate treatment but is not zero. You should attend recommended follow-up and continue checking your skin for changes even after your original tumour has been completely removed.
9. Why might OCT imaging be useful in the future?
OCT and LC-OCT may eventually help your dermatologist assess suspicious lesions non-invasively and reduce the need for some diagnostic biopsies. You should understand that this remains an evolving area of research and does not replace appropriate histological assessment in every case.
10. When should you seek specialist advice about a skin lesion?
You should arrange assessment if you notice a persistent lesion, a sore that does not heal, repeated bleeding or crusting, or another skin change that concerns you. Earlier assessment can help your specialist establish the diagnosis and discuss the most appropriate treatment.
Final Thoughts: What Should the OCTOPUS and Mohs Evidence Mean for You?
The OCTOPUS study and the Mohs-versus-excision trials answer different questions, so you should not treat them as the same research. OCTOPUS explores whether advanced imaging can improve your diagnostic pathway, while separate randomised evidence helps your specialist decide when Mohs or standard excision may provide the most appropriate surgical approach.
If you’d like to book a consultation with a dermatologist in London, you can contact us at the London Dermatology Centre.
References:
- Peleva, E. et al. (2025) ‘The OCTOPUS study (Optical Coherence Tomography in OutPatient dermatology UnitS): can noninvasive imaging improve diagnosis of keratinocyte (pre)cancers in immunosuppressed and immunocompetent patients?’, British Journal of Dermatology, 193(Supplement 1). Available at: https://academic.oup.com/bjd/article/193/Supplement_1/ljaf085.418/8161961
- ISRCTN Registry (2026) ‘ISRCTN15698540: Accuracy of diagnosing skin cancers with non-invasive optical coherence tomography (OCT) and line-field confocal OCT (LC-OCT) imaging compared to skin biopsy’. Available at: https://www.isrctn.com/ISRCTN15698540
- Smeets, N.W.J. et al. (2004) ‘Surgical excision vs Mohs’ micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial’, The Lancet, 364(9447), pp. 1766–1772. Available at: https://pubmed.ncbi.nlm.nih.gov/15541449/
- Mosterd, K. et al. (2008) ‘Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up’, The Lancet Oncology, 9(12), pp. 1149–1156. Available at: https://pubmed.ncbi.nlm.nih.gov/19010733/
- van Loo, E. et al. (2014) ‘Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up’, European Journal of Cancer, 50(17), pp. 3011–3020. Available at: https://pubmed.ncbi.nlm.nih.gov/25262378/
- Nasr, I. et al. (2021) ‘British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021’, British Journal of Dermatology, 185(5), pp. 899–920. Available at: https://academic.oup.com/bjd/article/185/5/899/6599942